Real‐World Assessment of Trilaciclib for the Prevention of Chemoradiotherapy‐Induced Myelosuppression in Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study

Documenti analoghi

• Nimotuzumab Combined With Concurrent Curative Radiotherapy and S‐1 in 75 Years and Older Patients With Stage II ‐ IVB Esophageal Squamous Cell Carcinoma: A Phase II Study
  di: Xiaojie Xia, et al.
  Pubblicazione: (2026)
• Clinical Implications of Nutritional Intake in Patients With Esophageal Squamous Cell Carcinoma Receiving Chemoradiotherapy and Neoadjuvant Chemotherapy
  di: Yumiko Tamai, et al.
  Pubblicazione: (2026)
• Prognostic Factors in Patients With Locally Advanced Hypopharyngeal Squamous Cell Carcinoma After Radical Radiotherapy/Chemoradiotherapy
  di: Xinyue Qu, et al.
  Pubblicazione: (2025)
• Prognosis Prediction and Surgical Benefit Subgroup Analysis in Anal Squamous Cell Carcinoma Patients Undergoing Concurrent Chemoradiotherapy
  di: Quan Wang, et al.
  Pubblicazione: (2025)
• Application of Esophageal Sponge Cytology in Screening Esophageal Squamous Cell Carcinoma in a High‐Risk Region of China
  di: Shu Huang, et al.
  Pubblicazione: (2025)